Arbutus Biopharma Corp ABUS

Healthcare Biotechnology

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is leveraging its virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV) infection. Its HBV product pipeline includes Imdusiran and AB-101. Imdusiran is its proprietary, conjugated GalNAc, subcutaneously delivered RNAi therapeutic product candidate. AB-101 is an oral PD-L1 inhibitor that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. Its pipeline includes two product candidates that target various steps in the HBV viral lifecycle and consists of various programs: RNAi therapeutic (imdusiran, AB-729) and Oral PD-L1 Inhibitor (AB-101). RNAi therapeutics utilize a natural pathway within cells to silence genes by eliminating the disease-causing proteins that they code for.

NDAQ:ABUS - Post by User

Arbutus Biopharma Corp

Bullboard Posts

Comment by HARLEYDAVIDSON21on Sep 26, 2014 5:24pm

212 Views

Post# 22975071

RE:Strange

Pharma stocks are the only stocks to own right now ,IMO.

I've dumped most of my mining and energy stocks to buy pharma,except for some penny stocks that aren't worth selling. :)

I own shares in 7 pharma stocks that are doing quite well right now and have consistently moved up in $$$.

Having said that ,I've stated before that the market will be extremely volatile for the next year or so..........especially for TKM....because of the uncertainty of this Ebola issue.

Of all my pharma stocks,TKM is the one that I can see jumping to $35-40 and then dropping again to the mid $20s...........I doubt we'll see the teens again,unless something drastic happens
.
People are going to have some patience and not panic. :)

Bullboard Posts

One of the best Venture pharma stocks has grown even stronger